PEK
0.325
170.8%
JAY
0.001
-50%
CHM
0.008
60%
LNR
0.001
-50%
AJL
0.008
33.3%
ECS
0.009
-25%
ATX
0.07
27.3%
ERL
0.003
-25%
EDU
0.165
26.9%
OSL
0.003
-25%
HCF
0.033
26.9%
RMY
0.026
-21.2%
SHP
0.005
25%
DTM
0.004
-20%
8CO
0.017
21.4%
HTA
0.02
-20%
EPM
0.006
20%
RDN
0.004
-20%
IPT
0.006
20%
ORD
0.41
-18%
MEM
0.006
20%
EVR
0.005
-16.7%
FRM
0.285
18.8%
KPO
0.005
-16.7%
H2G
0.013
18.2%
NWM
0.01
-16.7%
LMG
0.013
18.2%
ROG
0.005
-16.7%
PCL
0.013
18.2%
AZ9
0.027
-15.6%
RMI
0.013
18.2%
FFF
0.006
-14.3%
E79
0.027
17.4%
HHR
0.006
-14.3%
HE8
0.014
16.7%
KLI
0.03
-14.3%
1AE
0.074
15.6%
KNB
0.078
-14.3%
NIM
0.115
15%
PGY
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BOT successful completion of human factors validation study

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) announces that the Company has successfully completed the planned human factors validation study assessing the revised Instructions for Use for Sofpironium Bromide gel https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02753854-6A1186430 #shorts